- Home
- TRMD vs CLDX Comparison
TRMD vs CLDX Comparison
Compare TRMD & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | CLDX |
|---|---|---|
| Founded | 1889 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2016 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TRMD | CLDX |
|---|---|---|
| Price | $39.31 | $29.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $41.50 | ★ $63.07 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 11.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | $13.92 | $19.74 |
| Revenue Next Year | N/A | $438.11 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $19.30 | $22.10 |
| 52 Week High | $41.86 | $45.14 |
Technical Indicators
Market Signals| Indicator | TRMD | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 40.79 |
| Support Level | $28.19 | $28.51 |
| Resistance Level | $41.86 | $32.16 |
| Average True Range (ATR) | 1.29 | 1.42 |
| MACD | -0.34 | 0.25 |
| Stochastic Oscillator | 48.78 | 39.43 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.